Alendronate-induced Disruption of Actin Cytoskeleton and Inhibition of Migration/invasion Are Associated with Cofilin Downregulation in PC-3 Prostate Cancer Cells

Overview

Journal Oncotarget

Specialty Oncology

Date 2018 Sep 18

PMID 30220968

Citations 10

Authors

Sanna S Virtanen

Tamiko Ishizu

Jouko A Sandholm

Eliisa Loyttyniemi

H Kalervo Vaananen

Johanna M Tuomela

Pirkko L Harkonen

Affiliations

Soon will be listed here.

Abstract

Bisphosphonates are used for prevention of osteoporosis and metastatic bone diseases. Anti-invasive effects on various cancer cells have also been reported, but the mechanisms involved are not well-understood. We investigated the effects of the nitrogen-containing bisphosphonate alendronate (ALN) on the regulation of actin cytoskeleton in PC-3 cells. We analyzed the ALN effect on the organization and the dynamics of actin, and on the cytoskeleton-related regulatory proteins cofilin, p21-associated kinase 2 (PAK2), paxillin and focal adhesion kinase. Immunostainings of cofilin in ALN-treated PC-3 cells and xenografts were performed, and the role of cofilin in ALN-regulated F-actin organization and migration/invasion in PC-3 cells was analyzed using cofilin knockdown and transfection. We demonstrate that disrupted F-actin organization and decreased cell motility in ALN-treated PC-3 cells were associated with decreased levels of total and phosphorylated cofilin. PAK2 levels were also lowered but adhesion-related proteins were not altered. The knockdown of cofilin similarly impaired F-actin organization and decreased invasion of PC-3 cells, whereas in the cells transfected with a cofilin expressing vector, ALN treatment did not decrease cellular cofilin levels and migration as in mock transfected cells. ALN also reduced immunohistochemical staining of cofilin in PC-3 xenografts. Our results suggest that reduction of cofilin has an important role in ALN-induced disruption of the actin cytoskeleton and inhibition of the PC-3 cell motility and invasion. These data also support the idea that the nitrogen-containing bisphosphonates could be efficacious in inhibition of prostate cancer invasion and metastasis, if delivered in a pharmacological formulation accessible to the tumors.

Citing Articles

Regulation of Cancer Metastasis by PAK2.

Wu M, Sarkar C, Guo B Int J Mol Sci. 2025; 25(24.

PMID: 39769207 PMC: 11676821. DOI: 10.3390/ijms252413443.

Tubulin-Targeted Therapy in Melanoma Increases the Cell Migration Potential by Activation of the Actomyosin Cytoskeleton─An In Vitro Study.

Luty M, Szydlak R, Pabijan J, Zemla J, Oevreeide I, Prot V ACS Biomater Sci Eng. 2024; 10(11):7155-7166.

PMID: 39436192 PMC: 11558564. DOI: 10.1021/acsbiomaterials.4c01226.

1,25-Dihydroxyvitamin D Suppresses Prognostic Survival Biomarkers Associated with Cell Cycle and Actin Organization in a Non-Malignant African American Prostate Cell Line.

Johnson J, Martini R, Yuan Y, Woods-Burnham L, Walker M, Ortiz-Hernandez G Biology (Basel). 2024; 13(5).

PMID: 38785827 PMC: 11118023. DOI: 10.3390/biology13050346.

Investigating the Differential Circulating microRNA Expression in Adolescent Females with Severe Idiopathic Scoliosis: A Proof-of-Concept Observational Clinical Study.

Raimondi L, De Luca A, Gallo A, Perna F, Cuscino N, Cordaro A Int J Mol Sci. 2024; 25(1).

PMID: 38203740 PMC: 10779108. DOI: 10.3390/ijms25010570.

Involvement of lncRNAs in cancer cells migration, invasion and metastasis: cytoskeleton and ECM crosstalk.

Ahmad M, Weiswald L, Poulain L, Denoyelle C, Meryet-Figuiere M J Exp Clin Cancer Res. 2023; 42(1):173.

PMID: 37464436 PMC: 10353155. DOI: 10.1186/s13046-023-02741-x.

References

Jiang N, Hjorth-Jensen K, Hekmat O, Iglesias-Gato D, Kruse T, Wang C . In vivo quantitative phosphoproteomic profiling identifies novel regulators of castration-resistant prostate cancer growth. Oncogene. 2014; 34(21):2764-76. DOI: 10.1038/onc.2014.206. View

Salzano G, Marra M, Porru M, Zappavigna S, Abbruzzese A, La Rotonda M . Self-assembly nanoparticles for the delivery of bisphosphonates into tumors. Int J Pharm. 2010; 403(1-2):292-7. DOI: 10.1016/j.ijpharm.2010.10.046. View

Rodan G, Balena R . Bisphosphonates in the treatment of metabolic bone diseases. Ann Med. 1993; 25(4):373-8. DOI: 10.3109/07853899309147299. View

Wang W, Eddy R, Condeelis J . The cofilin pathway in breast cancer invasion and metastasis. Nat Rev Cancer. 2007; 7(6):429-40. PMC: 4270061. DOI: 10.1038/nrc2148. View

Virtanen S, Sandholm J, Yegutkin G, Vaananen H, Harkonen P . Inhibition of GGTase-I and FTase disrupts cytoskeletal organization of human PC-3 prostate cancer cells. Cell Biol Int. 2010; 34(8):815-26. DOI: 10.1042/CBI20090288. View

Marra M, Salzano G, Leonetti C, Tassone P, Scarsella M, Zappavigna S . Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes. Nanomedicine. 2011; 7(6):955-64. DOI: 10.1016/j.nano.2011.03.004. View

Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino F, Delmas P . Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res. 1997; 57(18):3890-4. View

Tsagozis P, Eriksson F, Pisa P . Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages. Cancer Immunol Immunother. 2008; 57(10):1451-9. PMC: 11030129. DOI: 10.1007/s00262-008-0482-9. View

Nishimura S, Tsuda H, Kataoka F, Arao T, Nomura H, Chiyoda T . Overexpression of cofilin 1 can predict progression-free survival in patients with epithelial ovarian cancer receiving standard therapy. Hum Pathol. 2011; 42(4):516-21. DOI: 10.1016/j.humpath.2010.07.019. View

10.

Hensley P, Zetter D, Horbinski C, Strup S, Kyprianou N . Association of epithelial-mesenchymal transition and nuclear cofilin with advanced urothelial cancer. Hum Pathol. 2016; 57:68-77. PMC: 5629972. DOI: 10.1016/j.humpath.2016.06.020. View

11.

Hashimoto K, Morishige K, Sawada K, Tahara M, Kawagishi R, Ikebuchi Y . Alendronate inhibits intraperitoneal dissemination in in vivo ovarian cancer model. Cancer Res. 2005; 65(2):540-5. View

12.

Lee M, Fong E, Singer F, Guenette R . Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res. 2001; 61(6):2602-8. View

13.

Brown M, Turner C . Paxillin: adapting to change. Physiol Rev. 2004; 84(4):1315-39. DOI: 10.1152/physrev.00002.2004. View

14.

Benford H, Frith J, Auriola S, Monkkonen J, Rogers M . Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol. 1999; 56(1):131-40. DOI: 10.1124/mol.56.1.131. View

15.

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

16.

Matsunaga S, Iguchi K, Usui S, Hirano K . Incadronate induces cell detachment and apoptosis in prostatic PC-3 cells. Anticancer Res. 2007; 27(2):927-32. View

17.

Wang F, Wu D, He F, Fu H, Xu J, Chen J . Study on the significance of Cofilin 1 overexpression in human bladder cancer. Tumori. 2016; 103(6):537-542. DOI: 10.5301/tj.5000569. View

18.

Rogers M, Kalra S, Moukharskaya J, Chakraborty K, Niyazi M, Krishnan K . Synergistic growth inhibition of PC3 prostate cancer cells with low-dose combinations of simvastatin and alendronate. Anticancer Res. 2015; 35(4):1851-9. View

19.

Chen H, Bernstein B, Bamburg J . Regulating actin-filament dynamics in vivo. Trends Biochem Sci. 2000; 25(1):19-23. DOI: 10.1016/s0968-0004(99)01511-x. View

20.

Kanellos G, Frame M . Cellular functions of the ADF/cofilin family at a glance. J Cell Sci. 2016; 129(17):3211-8. DOI: 10.1242/jcs.187849. View